



OPEN ACCESS

EDITED BY

Lina Zhao,
Tianjin Medical University General Hospital,
China

REVIEWED BY

Antonius Hocky Pudjadi,
University of Indonesia, Indonesia
Uvaraj Periasamy,
Boston Children's Hospital and Harvard
Medical School, United States

*CORRESPONDENCE

Chunmei Jing
✉ jcm791203@163.com
Yueqiang Fu
✉ 480887@hospital.cqmu.edu.cn

RECEIVED 06 September 2024

ACCEPTED 14 January 2025

PUBLISHED 03 February 2025

CITATION

Chen J, Huang H, Zhang R, Fu Y and Jing C (2025) Risk factors associated with mortality and pathogen characteristics of bloodstream infection-induced severe sepsis in the pediatric intensive care unit: a retrospective cohort study. *Front. Cell. Infect. Microbiol.* 15:1492208. doi: 10.3389/fcimb.2025.1492208

COPYRIGHT

© 2025 Chen, Huang, Zhang, Fu and Jing. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Risk factors associated with mortality and pathogen characteristics of bloodstream infection-induced severe sepsis in the pediatric intensive care unit: a retrospective cohort study

Jian Chen^{1,2}, Haixin Huang¹, Ruichen Zhang¹, Yueqiang Fu^{1*} and Chunmei Jing^{3*}

¹Department of Critical Care Medicine, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China, ²Department of Pediatric Critical Care Medicine, Sichuan Provincial Women's and Children's Hospital, Chengdu, China, ³Department of Clinical Laboratory, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity, Chongqing, China

Background: Bloodstream infection (BSI)-induced severe sepsis is a common cause of mortality, frequently resulting in septic shock and multiple organ dysfunction syndrome (MODS). This study aimed to analyze mortality risk factors and summarize pathogen characteristics associated with BSI-induced severe sepsis in the pediatric intensive care unit (PICU).

Methods: This retrospective study was conducted at a tertiary pediatric hospital between January 2015 and December 2023, encompassing children with BSI-induced severe sepsis in the PICU. Clinical characteristics, laboratory parameters, pathogen characteristics, and drug resistance profiles of the patients were collected. Clinical and laboratory indicators along with pathogen characteristics were summarized. Logistic regression analysis was employed to identify independent risk factors associated with 28-day mortality.

Results: A total of 192 patients with bloodstream infection (BSI)-induced severe sepsis were identified, with a 28-day in-hospital mortality rate of 36.98% (71/192). The incidence of septic shock (42.1% vs. 69%, $P < 0.001$) and AKI (14% vs. 31%, $P = 0.005$) was significantly lower in the survival group compared to the non-survival group. In multivariate analysis, independent risk factors for 28-day mortality were the pediatric sequential organ failure assessment (pSOFA) score (OR 1.176; 95% CI: 1.046-1.321, $p = 0.007$) and the P/F value (OR 0.994; 95% CI: 0.991-0.997, $P < 0.001$). Double organism growth was detected in 8 cultures, and a total of 200 pathogenic bacteria were isolated from all blood cultures. Of these, 110 strains (55.0%) were Gram-negative bacteria, 88 strains (44.0%) were gram-positive

bacteria, and 2 strains (1.0%) were *Candida albicans*. The most commonly isolated pathogens were *Staphylococcus aureus*, *Coagulase-negative Staphylococcus*, and *Escherichia coli*. The detection rate of carbapenem resistance (CR) in *Acinetobacter baumannii* (66.7%) was higher than that in *Pseudomonas aeruginosa* (15.4%). The detection rates of extended-spectrum cephalosporin resistance (ECR) and fluoroquinolone resistance (FQR) in *Escherichia coli* (*E. coli*) were higher than those in *Klebsiella pneumoniae*.

Conclusion: In the PICU, higher mortality was observed in children with BSI-induced severe sepsis who presented with elevated pSOFA scores and low P/F values. *Acinetobacter baumannii* exhibited the highest levels of CR and FQR, while *Escherichia coli* demonstrated the highest level of ECR.

KEYWORDS

bloodstream infection, sepsis, risk factors, intensive care units, children, mortality

1 Introduction

Bloodstream infection (BSI) is defined as the presence of microorganisms in the bloodstream, as confirmed by a positive blood culture (BC) in a patient exhibiting clinical signs of infection (Laupland and Leal, 2020). Sepsis is a life-threatening condition resulting from a dysregulated immune response to infection that leads to organ dysfunction (Singer et al., 2016; Rhee et al., 2019). In 2020, the World Health Organization (WHO) reported that sepsis affects 49 million people and causes 11 million deaths globally each year, with many of the victims being children. Sepsis also disables millions more. The WHO recognized sepsis as a major public health issue and urged all United Nations (UN) member states to enhance sepsis prevention, recognition, and management (Singer et al., 2016; Rudd et al., 2020; World Health Organization, 2020). In recent years, the incidence of bloodstream infections (BSI) has been increasing, particularly among the young and elderly populations (Kontula et al., 2021). Approximately one out of three episodes of bacteremia are associated with organ dysfunction, according to a recent large population-based study. BSI-induced severe sepsis is a common cause of death and frequently results in septic shock and multiple organ dysfunction syndrome (MODS) (Weiss et al., 2020; Agyeman et al., 2017). BSI or septic shock remain an important cause of morbidity and mortality (Weiss et al., 2015; Martín-Torres et al., 2018), with mortality rates reported as high as 40% (Weiss et al., 2015; Wang et al., 2014; Dou et al., 2024; Allel et al., 2023). Multiple analyses indicate that BSIs in the ICU significantly increase both the length of stay (LOS) and healthcare costs (Goudie et al., 2014; Timsit et al., 2020; Tabah et al., 2022). Bloodstream infection (BSI) presents a major challenge in the critically ill (Munro et al., 2024). Infection prevention and control efforts should prioritize preventing BSIs in the youngest age groups, particularly in neonatal and pediatric intensive care units (Zingg et al., 2017).

Bloodstream infections (BSI) can be caused by a variety of pathogens, and the microbiology of ICU BSIs varies globally (Munro et al., 2024). Understanding the clinical features and distribution of pathogenic bacteria in BSI-induced severe sepsis in local ICUs is crucial for treating severely infected children. In this study, we conducted a retrospective analysis to identify the risk factors for mortality and to characterize the pathogens associated with BSI-induced severe sepsis in the pediatric intensive care unit (PICU).

2 Material and methods

2.1 Study design

This retrospective study was conducted using clinical data of children with BSI-induced severe sepsis in the pediatric intensive care unit (PICU) at a tertiary pediatric hospital between January 2015 and December 2023. This study was approved by the Institutional Review Board of the hospital. Patient data were anonymized and de-identified prior to analysis. Due to the retrospective nature of the study, the requirement for informed CoNSent was waived. The inclusion criteria were as follows: 1) patients aged 1 month to 18 years admitted to the PICU, 2) positive blood culture during hospitalization, and 3) meeting the diagnostic criteria for severe sepsis in children. The exclusion criteria were: 1) negative blood culture during hospitalization, and 2) isolated organisms identified as contaminants or fixed values.

2.2 Microbiologic methods

Blood samples were collected from peripheral veins of the central venous catheter. Each 1-5 mL blood sample was immediately

inoculated into a culture bottle and transported to the laboratory. Blood cultures were processed BD BACTEC FX 400 automatic bacteria culture system. Drug susceptibility tests were performed using the conventional minimum inhibitory concentration (MIC) test with BD phoenix TM 100 automated microbiology system. This study was to examine the prevalence of four important drug-resistance phenotypes: difficult-to-treat resistance (DTR), fluoroquinolone resistance (FQR), carbapenem resistance (CR), and extended-spectrum cephalosporin resistance (ECR).

2.3 Data collection

We collected the laboratory indicators and scores within 24 hours of the first positive blood culture sample sent for testing. The following demographic and laboratory data were collected: age, body weight, gender, white blood cell (WBC), C-reactive protein (CRP), Procalcitonin (PCT), albumin (ALB), and serum creatinine (SCr). The P/F value ($\text{PaO}_2/\text{FiO}_2$), pediatric sequential organ failure assessment (pSOFA) scores (Mohamed El-Mashad et al., 2020), International Society on Thrombosis and Hemostasis (ISTH) disseminated intravascular coagulation (DIC) scores, sepsis-induced coagulopathy (SIC) scores, underlying conditions, and Nosocomial infection were obtained. Comorbidities such as septic shock, respiratory failure, liver function impairment, and acute kidney injury (AKI) were also evaluated. Furthermore, data on the need for continuous renal replacement therapy (CRRT) and mechanical ventilation (MV), duration of CRRT and MV, as well as length of hospital stay and stay in the PICU were recorded.

2.4 Definitions

Sepsis: SIRS in the presence of or as a result of suspected or proven infection. Severe sepsis: sepsis plus one of the following: cardiovascular organ dysfunction or acute respiratory distress syndrome or two or more other organ dysfunctions. Septic shock: sepsis and cardiovascular organ dysfunction, cardiovascular dysfunction: despite administration of isotonic intravenous fluid bolus 40 mL/kg in 1 hr., decrease in BP (hypotension) 5th percentile for age or systolic BP 2 SD below normal for age, or need for vasoactive drug to maintain BP in normal range (dopamine 5 g/kg/min or dobutamine, epinephrine, or norepinephrine at any dose), or two of the following: 1. Unexplained metabolic acidosis: base deficit 5.0 mEq/L. 2. Increased arterial lactate 2 times upper limit of normal; 3. Oliguria: urine output 0.5 mL/kg/hr. 4. Prolonged capillary refill: 5 secs. 5. Core to peripheral temperature gap 3°C (Goldstein et al., 2005). Nosocomial infection was defined as the first positive blood culture was drawn after day 2 of the hospital admission, with no primary diagnosis of infectious disease present on admission (as defined with International Classification of Disease (ICD) diagnosis codes and Major Diagnostic Categories). Respiratory failure is the inability of the respiratory system to maintain oxygenation or eliminate carbon dioxide, resulting in hypoxemia ($\text{PaO}_2 < 60$ mmHg) with or without hypercapnia ($\text{PaCO}_2 > 50$ mmHg), or the need for noninvasive or

invasive ventilator support. Liver function impairment was defined as transaminase levels three times above the upper limit of normal. Acute kidney injury is defined as an increase in serum creatinine levels by at least 0.3 mg/dl within 48 hours or 1.5-fold the baseline, which is known or presumed to have occurred within the preceding 7 days, or according to the urine output criterion—urine volume less than 0.5 ml/kg/hour for at least 6 hours. Contaminants: The most frequently identified contaminants in cultures were *Staphylococcus epidermidis* and *Staphylococcus hominis*. Critical value reports from blood cultures were systematically monitored, and clinicians assessed whether these organisms were true pathogens or contaminants based on the patient's clinical presentation and relevant laboratory parameters. Difficult-to-treat resistance (DTR) was defined as resistance or intermediate resistance *in vitro* to all β -lactam categories, including carbapenems and fluoroquinolones. Carbapenem resistance (CR) was defined as resistance *in vitro* to imipenem or meropenem. Extended-spectrum cephalosporin resistance (ECR) was defined as resistance *in vitro* to ceftriaxone or cefepime (excluding natural drug resistance). Fluoroquinolone resistance (FQR) was defined as resistance *in vitro* to ciprofloxacin or levofloxacin.

2.5 Outcomes analysis

The primary outcome was 28-day in-hospital mortality, and the secondary outcome was the distribution of pathogens in bloodstream infection-induced severe sepsis.

2.6 Statistical analysis

Raw data was firstly processed by Whonet 5.6 software. Data processing was performed using Graphpad Prism 8.4.2 for Windows (GraphPad Software, San Diego, California, USA) and SPSS 26.0 software packages (IBM Corp., Armonk, NY, USA). We used the median (interquartile range or IQR) and proportion (percentage) to describe continuous and categorical data, respectively. The Mann-Whitney U test was used to compare two medians, and the chi-square test was used to compare proportions. Multiple logistic regression was employed to identify independent risk factors, controlling for confounding variables. Statistical significance was defined as $P < 0.05$ (two-tailed).

3 Result

3.1 Study population

During the study period, a total of 9032 blood cultures were collected from patients suspected of bloodstream infections (BSI). Among these, 382 cultures tested positive. After excluding possible contaminants and duplicates, we analyzed 200 episodes confirmed as bloodstream infections leading to severe sepsis. The annual positive rates in the 9 years from 2015 to 2023 were 3.09%, 3.96%, 3.05%, 2.83%, 1.51%, 1.38%, 1.93%, 2.18%, and 1.43%, respectively (Figure 1).




FIGURE 1

Annual number of blood cultures including the submitted specimens and positive specimens, from 2015 to 2023.

3.2 Characteristics of patients diagnosed with BSI-induced severe sepsis

One hundred and ninety-two cases of bloodstream infection-induced severe sepsis were identified. The clinical characteristics of these patients are summarized in Table 1. We categorized the children into survival and non-survival groups, and their clinical characteristics are presented in Table 1. The 28-day in-hospital mortality rate was 36.98% (71/192).

The median age of these patients, of whom 114 (59.4%) were male, was 16 (6–84) months and the median weight was 10.25 (7–22.75) kg. Septic shock was present in 100 cases (52.1%), respiratory failure in 158 cases (82.3%), liver function impairment in 108 cases (56.3%), acute kidney injury in 39 cases (20.3%), and underlying conditions were present in 51 cases (26.6%) at presentation.

During the 28-day hospital stay, 71 patients (36.98%) died. The endpoint of the study was the 28-day in-hospital mortality (all-cause). Patients discharged from the hospital within 28 days were deemed alive unless proven otherwise. When comparing the survival and non-survival groups, in terms of laboratory tests, there was no significant difference in CRP. There were also no significant differences in respiratory failure, liver function damage, underlying conditions, gram-positive bacteria and nosocomial infection. Additionally, the requirements of MV and CRRT were similar between the two groups.

The levels of WBC (9.67 vs. $5.96 \times 10^9/L$, $P < 0.001$), ALB (30.4 vs. 26.4 g/l, $P < 0.001$), and P/F value (345.71 vs. 147.06, $P < 0.001$) in the survival group were significantly higher than in the no-survival group, while the opposite was true for PCT (6.34 vs. 14.54 ng/ml, $P = 0.039$), SCr (28.2 vs. 41 mmol/l, $P < 0.001$), pSOFA (8 vs. 12, $P < 0.001$), ISTH-DIC (3 vs. 5, $P < 0.001$), and SIC (3 vs. 4, $P < 0.001$). The prevalence of septic shock (42.1% vs. 69%, $P < 0.001$) and acute kidney injury (14% vs. 31%, $P = 0.005$) in the survival group were

significantly lower than in the non-survival group. Compared with the two groups, LOS (30 vs. 4 days, $P = 0.001$) and PICU stay (12 vs. 3 days, $P < 0.001$) in survival the group were significantly higher than in the no-survival group.

3.3 Analyses of risk factors for 28-day in-hospital mortality of BSI

Univariate analysis revealed that ALB, pSOFA, P/F value, Septic shock, and AKI were associated with 28-day in-hospital mortality (Table 2). Multivariate analysis further showed that pSOFA (OR 1.176; 95% CI: 1.046–1.321, $p = 0.007$) and P/F value (OR 0.994; 95% CI: 0.991–0.997, $P < 0.001$) were independently correlated with 28-day in-hospital mortality (Table 2). Conversely, septic shock and AKI were not identified as independent risk factors for 28-day in-hospital mortality.

3.4 Microbial findings

During the study period, a total of 200 pathogenic bacteria were isolated from blood cultures in PICU. Among these, 110 strains (55.0%) were identified as Gram-negative bacteria, 88 strains (44.0%) were identified as gram-positive bacteria, and 2 strains (1%) were identified as *Candida albicans* (Table 3, Figure 2). Double organism growth was detected in 8 cultures. The most commonly isolated pathogens were *Staphylococcus aureus*, *Coagulase-negative Staphylococcus*, and *Escherichia coli*. Among Gram-negative bacteria, *Escherichia coli* (21 strains, 10.5%), *Pseudomonas aeruginosa* (19 strains, 9.5%), *Klebsiella pneumoniae* (18 strains, 9.0%), and *Acinetobacter baumannii* (18 strains, 9.0%) were the most prevalent. Among gram-positive bacteria, *Staphylococcus*

TABLE 1 Clinical characteristics and outcomes associated with blood culture-proven bacterial sepsis in 192 children.

	All patients (n=192)	Survivors (n=121)	Non-survivors (n=71)	P value
Basic information				
Age(month) (median, IQR)	16(6-84)	18(7-84)	11(6-96)	0.571
Weight, (kg) (median, IQR)	10.25(7-22.75)	11(7-23)	10(7-22)	0.735
Gender, (male) n (%)	114(59.4%)	73(60.3%)	41(57.7%)	0.726
Laboratory index				
WBC($\times 10^9/L$) (median, IQR)	8.41(4.59-15.19)	9.67(6.07-16.5)	5.96(1.55-12.47)	<0.001
CRP (mg/l) (median, IQR)	33(8-73)	30(8.93-73.5)	34(8-64)	0.747
PCT (ng/ml) (median, IQR)	9.21(1.38-55)	6.34(0.79-55)	14.54(2.60-98.44)	0.039
ALB (g/l) (median, IQR)	28.4(23.88-33.78)	30.4(25.5-36.3)	26.4(21.7-29.6)	<0.001
SCr (mmol/l) (median, IQR)	32.1(21.1-55.38)	28.2(18.2-47.75)	41(25-78.8)	<0.001
P/F value (median, IQR)	308.04(164.76-407.68)	345.71(259.57-431.95)	147.06(84.29-323.75)	<0.001
pSOFA (median, IQR)	9(6-12)	8(5-10)	12(8-14)	<0.001
ISTH-DIC (median, IQR)	3(3-5)	3(2-4)	5(3-6)	<0.001
SIC (median, IQR)	4(2-5)	3(2-4)	4(3-6)	<0.001
Clinical presentation				
Septic shock (n, %)	100(52.1%)	51(42.1%)	49(69%)	<0.001
Respiratory failure (n, %)	158(82.3%)	98(81%)	60(84.5%)	0.539
Liver function damage (n, %)	108(56.3%)	63(52.1%)	45(63.4%)	0.128
AKI (n, %)	39(20.3%)	17(14%)	22(31%)	0.005
*Underlying conditions (n, %)	51(26.6%)	28(23.1%)	23(32.4%)	0.162
Nosocomial infection (n, %)	74(38.5%)	50(41.3%)	24(33.8%)	0.303
*GPB (n, %)	86 (44.8%)	54 (44.6%)	32 (45.1%)	0.953
MV (n, %)	167(87%)	105(86.8%)	62(87.3%)	0.914
CRRT (n, %)	48(25%)	26(21.5%)	22(31%)	0.143
LOS (days) (median, IQR)	18(5-35.75)	30(17.5-43)	4(2-13)	0.001
PICU stay (days) (median, IQR)	7.5(3-17)	12(5-25)	3(1-7)	<0.001

AKI, acute kidney injury; ALB, albumin; CRP, C-reactiveprotein; CRRT, continuous renal replacement therapy; DIC, disseminated intravascular coagulation; Fib, fibrinogen; GPB, gram-positive bacteria; MV, mechanical ventilation; IQR, inter quartile range; ISTH, international society on thrombosis and haemostasis; Los, Length of stay; PCT, Procalcitonin; P/F value, PaO₂/FiO₂; PICU, Pediatric intensive care unit; pSOFA, pediatric sequential organ failure assessment; SCr, serum creatinine; SIC, Sepsis-induced coagulopathy scores; WBC, White blood cell.

*GPB: Double organism growth was detected in 8 cultures, determine whether the pathogen was Gram-positive or Gram-negative based on the results of the first blood culture.

*Underlying conditions: children with underlying comorbidities, in this study, the underlying diseases include hematologic malignancies, bone marrow transplantation, rheumatic and autoimmune diseases, primary immunodeficiencies, malnutrition, and diabetes mellitus.

aureus (25 strains, 12.5%), *Coagulase-negative Staphylococcus* (25 strains, 12.5%), *Streptococcus pneumoniae* (15 strains, 7.5%), and *Enterococcus* (10 strains, 5.0%) were the most common.

3.5 Antimicrobial resistance pattern of main bacterial isolates

As depicted in Table 4, *Staphylococcus aureus* (*S. aureus*) showed a resistance of 95.0%, 23.1%, 4.8% and 65.0% to penicillin, tetracycline, trimethoprim-sulfamethoxazole and

erythromycin, respectively. The detection rate of methicillin resistant *Staphylococcus aureus* (MRSA) was 65.0%. *Coagulase-negative staphylococci* (CoNS) showed resistance rates $\geq 80\%$ to penicillin and erythromycin. *Streptococcus pneumoniae* (*SP*) exhibited the highest resistance rates to tetracycline (100%) and erythromycin (91.7%). *Enterococcus* showed 50.0% resistance to penicillin. Vancomycin or linezolid-resistant strains were not isolated in gram-positive bacteria.

As shown in Table 5, high frequencies of resistance to ampicillin-sulbactam (55.6%), aztreonam (52.9%), ceftriaxone (85.7%), and trimethoprim-sulfamethoxazole (72.2%) were

TABLE 2 Logistic regression analysis of risk factors for 28-day mortality in 192 children with BSI.

	Univariate analysis			Multivariate analysis		
	OR	95%CI	P value	OR	95%CI	P value
ALB	0.915	0.874-0.959	<0.001	0.949	0.898-1.002	0.061
pSOFA	1.328	1.203-1.467	<0.001	1.176	1.046-1.321	0.007*
P/F value	0.992	0.99-0.995	<0.001	0.994	0.991-0.997	<0.001*
Septic shock	3.057	1.646-5.677	<0.001	1.784	0.839-3.792	0.132
AKI	2.747	1.339-5.633	0.006	1.435	0.564-3.655	0.449

AKI, acute kidney injury; ALB, albumin; BSI, bloodstream infection; P/F value, PaO₂/FiO₂; pSOFA, pediatric sequential organ failure assessment.

*Indicates statistically significant results, $P < 0.05$.

observed among *Escherichia coli* (*E. coli*). Minimal resistance frequency of *E. coli* was detected to amikacin (0%), meropenem (17.1%), and piperacillin/tazobactam (16.7%). *Klebsiella pneumoniae* (*K. pneumoniae*) demonstrated a resistance of 11.1%, 38.5%, 38.5%, and 23.1% to amoxicillin/clavulanate, aztreonam, cefepime, and imipenem, respectively. *Pseudomonas aeruginosa* (*P. aeruginosa*) of the resistance rates was 14.3%, 7.7%, 7.7%, and 15.0% to amikacin, cefepime, levofloxacin, and imipenem, respectively. *Acinetobacter baumannii* (*A. baumannii*) showed resistance rates exceeding 50% against all tested antibiotics.

3.6 The distribution of special antimicrobial resistance phenotypes

As shown in Table 6 and Figure 3, the detection rates of CR, ECR, and FQR were 22.2%, 85.7%, and 47.1% in *E. coli*; 23.1%, 38.5%, and 15.4% in *K. pneumoniae*; 15.4%, 7.7%, and 7.7% in *P. aeruginosa*; and 66.7%, 81.8%, and 75.0% in *A. baumannii*, respectively. DTR strains were not isolated in main gram-

negative bacteria. The detection rate of CR in *A. baumannii* (66.7%) was higher than that in *P. aeruginosa* (15.4%). The detection rates of ECR and FQR in *E. coli* were higher than those in *K. pneumoniae*. *A. baumannii* exhibited the highest levels of CR and FQR, while *E. coli* demonstrated the highest level of ECR.


4 Discussion

In this study, the overall positive rate of blood cultures from 2015 to 2023 was 4.23%, which is consistent with findings from a previous study (Limmathurotsakul, 2017). After excluding contaminants and duplicates, the adjusted average positive rate of blood cultures was 2.21%. Sepsis can be induced by a wide range of pathogens, with bacterial infections accounting for the majority of cases. However, up to 42% of sepsis episodes are culture-negative (Lin et al., 2018), indicating the potential involvement of non-bacterial etiologies (Phua et al., 2013). Additionally, some studies have identified viruses as another significant cause of sepsis, particularly in pediatric populations (Lin et al., 2018), which may help explain the relatively low positive rate of blood cultures observed in our study. We conducted a retrospective analysis of clinical data from a single-center PICU over a 9-year period to investigate BSI-induced severe sepsis. The 28-day in-hospital mortality rate was 36.98%. Among the patients, 26.6% had underlying conditions, 82.3% experienced respiratory failure, 56.3% exhibited liver function impairment, 52.1% developed septic shock, and 20.3% suffered from acute kidney injury. In children with BSI-induced severe sepsis, mortality was higher in those with high pSOFA and low P/F values. The mortality rates for pediatric severe sepsis or septic shock have been reported as high as 40% (Weiss et al., 2015; Wang et al., 2014). A retrospective study analyzed 132 children with BSI-induced severe sepsis, revealing a mortality rate of 28.8% (Dou et al., 2024). Taddei et al. (Allel et al., 2023) recently noted crude mortality rates for ICU-acquired bloodstream infections exceeding 40%. In our study, the 28-day mortality rate was 36.98%. The SOFA score has been recommended by the Society of Critical Care Medicine and the European Society of Intensive Care Medicine for predicting mortality in sepsis. Specifically, a 2-point increase in the SOFA score is associated with a 10% increase in mortality (Shankar-Hari et al., 2016). A systematic review and meta-analysis noted that SOFA showed the

TABLE 3 Microbiology of BSI children admitted in the PICU.

Organism	Subjects n=200	%
Gram-negative bacteria	110	55.0
<i>E. coli</i>	21	10.5
<i>P. aeruginosa</i>	19	9.5
<i>K. pneumoniae</i>	18	9.0
<i>A. baumannii</i>	18	9.0
Gram-positive bacteria	88	44.0
<i>S. aureus</i>	25	12.5
CoNS	25	12.5
SP	15	7.5
<i>Enterococcus</i>	10	5.0
Fungi	2	1.0
<i>Candida albicans</i>	2	1.0

A. baumannii, *Acinetobacter baumannii*; CoNS, Coagulase-negative staphylococci; *E. coli*, *Escherichia coli*; *K. pneumoniae*, *Klebsiella pneumoniae*; *P. aeruginosa*, *Pseudomonas aeruginosa*; *S. aureus*, *Staphylococcus aureus*; SP, *Streptococcus pneumoniae*.



highest sensitivity and specificity in predicting in-hospital mortality in sepsis (Qiu et al., 2023). Our multivariate analysis revealed that both pSOFA (OR 1.176; 95% CI: 1.046-1.321, $p = 0.007$) and P/F value (OR 0.994; 95% CI: 0.991-0.997, $P < 0.001$) were independently correlated with 28-day in-hospital mortality.

Organ dysfunction syndrome commonly developed in severe sepsis and was associated with higher morbidity and mortality compared to severe sepsis without organ dysfunction syndrome (Lin et al., 2017). Agyeman et al. (2017) demonstrated a strong association between organ dysfunction and mortality, reporting a notable increase to 17% with at least one organ dysfunction and 29% with two or more organ dysfunctions. In our study, although not statistically significant, the survival group exhibited lower rates of respiratory failure and liver function impairment compared to the non-survival group. Septic shock (42.1% vs. 69%, $P < 0.001$) and acute kidney injury (14% vs. 31%, $P = 0.005$) were significantly less frequent in the survival group than in the non-survival group. These findings collectively indicate higher disease severity in the

non-survival group than in the survival group. Hence, continuous assessment of SOFA score, P/F value index, and preservation of organ function may enhance the prognosis of children with BSI-induced severe sepsis.

In this study, a total of 200 pathogenic bacteria were isolated from blood cultures in the PICU. Among these, 110 strains (55.0%) were identified as gram-negative bacteria, 88 strains (44.0%) as gram-positive bacteria, and 2 strains (1%) as *Candida albicans*. The most frequently isolated pathogens were *Staphylococcus aureus* (*S.aureus*) (12.5%), *Coagulase-negative Staphylococcus* (CoNS) (12.5%), and *Escherichia coli* (*E. coli*) (10.5%), consistent with findings from previous studies (Kontula et al., 2021; Dou et al., 2024; Fu et al., 2021). According to the Infectious Disease Surveillance of Pediatrics (ISPED) program in China from 2016 to 2020, a total of 288,377 clinical strains were isolated from 11 member units, with Gram-positive and Gram-negative bacteria accounting for 42.1% and 57.9%, respectively. Among these, the top two pathogenic bacteria derived from blood specimens were

TABLE 4 Antimicrobial resistance rates of main gram-positive bacteria isolated from patients investigated for BSI in PICU.

Bacterium	PEN (%)	OXA (%)	VAN (%)	TEC (%)	LZD (%)	TCY (%)	LVX (%)	RIF (%)	SXT (%)	CHL (%)	ERY (%)
<i>S.aureus</i> (n=25)	95.0	65.0	0	0	0	23.1	0	0	4.8	0	65.0
CoNS (n=25)	91.7	83.3	0	0	0	28.6	41.2	35.7	45.8	NA	81.0
SP (n=15)	8.3	NA	0	0	0	100	0	0	58.3	0	91.7
<i>Enterococcus</i> (n=10)	50.0	NA	0	0	0	60.0	42.9	NA	50.0	NA	50.0

CHL, chloramphenicol; CoNS, *Coagulase-negative staphylococci*; ERY, erythromycin; LVX, levofloxacin; LZD, linezolid; NA, not applicable; OXA, oxacillin; PEN, Penicillin G; R, resistance; RIF, rifampicin; *S.aureus*, *Staphylococcus aureus*; SP, *Streptococcus pneumoniae*; SXT, trimethoprim-sulfamethoxazole; TCY, tetracycline; TEC, teicoplanin; VAN, vancomycin.

TABLE 5 Antimicrobial resistance rates of main gram- negative bacteria isolated from patients investigated for BSI in PICU.

Bacterium	AMK (%)	AMC (%)	SAM (%)	ATM (%)	FEP (%)	CRO (%)	CIP (%)	LEV (%)	GEN (%)	MEM (%)	IPM (%)	TZP (%)	SXT (%)
<i>E. coli</i> (n=21)	0	36.4	55.6	52.9	29.4	85.7	47.1	44.4	27.8	17.1	22.2	16.7	72.2
<i>K. pneumoniae</i> (n=18)	23.1	11.1	30.8	38.5	38.5	25.0	15.4	8.3	23.1	20.0	23.1	23.1	23.1
<i>P. aeruginosa</i> (n=19)	14.3	100	100	9.1	7.7	100	7.7	7.7	14.3	15.4	15.0	14.3	100
<i>A. baumannii</i> (n=18)	62.5	100	90.0	100	72.7	81.8	75.0	58.3	75.0	60.0	66.7	50.0	66.7

A. baumannii, *Acinetobacter baumannii*; AMC, amoxicillin/clavulanate; AMK, amikacin; ATM, aztreonam; CIP, ciprofloxacin; CRO, ceftriaxone; *E. coli*, *Escherichia coli*; FEP, cefepime; GEN, gentamicin; IPM, imipenem; *K. pneumoniae*, *Klebsiella pneumoniae*; LEV, levofloxacin; MEM, meropenem; *P. aeruginosa*, *Pseudomonas aeruginosa*; SAM, ampicillin-sulbactam; SXT, trimethoprim-sulfamethoxazole; TZP, piperacillin/ tazobactam.

TABLE 6 The special antimicrobial resistance phenotypes of main gram- negative bacteria isolated from patients investigated for BSI in PICU. .

	<i>E. coli</i> (%)	<i>K. pneumoniae</i> (%)	<i>P. aeruginosa</i> (%)	<i>A. baumannii</i> (%)
DTR	0.0	0.0	0.0	0.0
CR	22.2	23.1	15.4	66.7
ECR	85.7	38.5	7.7	81.8
FQR	47.1	15.4	7.7	75.0

A. baumannii, *Acinetobacter baumannii*; CR, carbapenem resistance; DTR, difficult-to-treat resistance; *E. coli*, *Escherichia coli*; ECR, extended-spectrum cephalosporin resistance; FQR, fluoroquinolone resistance; *K. pneumoniae*, *Klebsiella pneumoniae*; *P. aeruginosa*, *Pseudomonas aeruginosa*.


CoNS (46.3%), and *E. coli* (6.0%) (Fu et al., 2021). A study conducted in PICUs in China on bloodstream infection pathogens reported 31.8% gram-positive bacteria, 65.9% gram-negative bacteria, and 2.27% fungi (Dou et al., 2024). In a population-based study of bloodstream infection, Kontula et al. (Kontula et al., 2021) showed among all BSIs, gram-positive bacteria caused 46% of infections, gram-negative bacteria 46%, fungi 1.5%. *E. coli* was the most common causative pathogen (29%), followed by *S. aureus* (13%), CoNS (8%).

There has been an increase in bacteremia caused by *S. aureus*, CoNS and gram-negative pathogens across all age groups in children (Pai et al., 2015). Several surveys had demonstrated a rising trend in multidrug-resistant bloodstream infections (MDR BSIs) over time (Kontula et al., 2021; de Kraker et al., 2013). In our study, we analyzed the antimicrobial resistance pattern of the main bacterial isolates. In resistance patterns, all the main gram-positive bacteria were susceptible to vancomycin and linezolid, similar to the study of ZY L et al (Lyu et al., 2023). *S. aureus* exhibited frequent resistance to Penicillin and erythromycin, while showing high susceptibility to glycopeptides. Some studies have noted inferior outcomes were reported in methicillin-susceptible *S. aureus* bacteremia (MSSA-B) treated with glycopeptides compared with β -lactams (McMullan et al., 2020; 2016; McDanel et al., 2015). In clinical practice, glycopeptides are preferred for methicillin-resistant *S. aureus* bacteremia (MRSA-B), whereas for MSSA-B, β -lactams should be preferred over glycopeptides.

Infections caused by resistant Gram-negative bacteria are increasingly concerning in both developing and developed countries (Pai et al., 2015). In present study, *E. coli* showed high resistance to aztreonam, ceftriaxone, cefuroxime and trimethoprim-sulfamethoxazole. Minimal resistance was observed in *E. coli* against amikacin, piperacillin/tazobactam, and meropenem,

consistent with findings from other studies (Dou et al., 2024; Legese et al., 2022). We observed an alarming resistance of *K. pneumoniae* to meropenem (20.0%), even higher than reported in another study (Legese et al., 2022). *A. baumannii* exhibited resistance rates exceeding 50% against all tested drugs, notably high resistance to meropenem (60.0%), consistent with previous studies (Dou et al., 2024; Legese et al., 2022).

The pathogens of bloodstream infection vary across regions, and multidrug resistance (MDR) poses a threat to public health.



Our study showed that the validity rate of the carbapenem-resistant *E. coli* (CR-ECO) was 22.2%, which was lower than that of the carbapenem-resistant *K. pneumoniae* (CR-KPN) (23.1%). Compared to the study by ZY L et al (Lyu et al., 2023), our detection rates of CRECO were higher, while the detection rates of CR-KPN were significantly lower. In our study, among the non-fermentative gram-negative bacilli isolates, 15.4% and 15% of the *P. aeruginosa*, were resistant to meropenem and imipenem. Furthermore, the resistance rates of *A. baumannii* to meropenem and imipenem were 60.0% and 66.7%. The detection rates of ECR and FQR in *E. coli* were higher than those in *K. pneumoniae*. *A. baumannii* exhibited the highest levels of CR and FQR, while *E. coli* demonstrated the highest level of ECR. In the study of ZY L et al (Lyu et al., 2023), *K. pneumoniae* demonstrated the highest level of ECR, *E. coli* the highest level of FQR, and *A. baumannii* the highest level of CR. There were significant differences in medication habits and drug resistance among different regions. Monitoring local multidrug resistance (MDR) and selecting antibiotics reasonably based on susceptibility testing were crucial.

5 Conclusion

In conclusion, among children with BSI-induced severe sepsis, higher mortality was observed in those with elevated pSOFA scores and lower P/F values. The common pathogen of BSI-induced severe sepsis in PICU is Gram-negative bacteria. The three most frequently isolated pathogens were *Staphylococcus aureus*, *Coagulase-negative Staphylococcus*, and *Escherichia coli*. The pathogens of bloodstream infection vary across regions, monitoring local multidrug resistance (MDR) and selecting antibiotics reasonably based on susceptibility testing were crucial.

6 Limitation

This study has several limitations. Firstly, being retrospective, it was confined to cases and data from a single center. Consequently, these findings may not generalize to centers with different patient populations or antibiotic profiles. Secondly, the study focused exclusively on patients with documented bloodstream infections, potentially introducing selection bias since not all bacteremia cases were confirmed by positive blood cultures. Thirdly, retrospective studies could not further explore the mechanism of MDR resistance, and we did not analyze the molecular mechanisms of the drug-resistant strains.

References

- Agyeman, P. K. A., Schlapbach, L. J., Giannoni, E., Stocker, M., Posfay-Barbe, K. M., Heining, U., et al. (2017). Epidemiology of blood culture-proven bacterial sepsis in children in Switzerland: a population-based cohort study. *Lancet Child Adolesc. Health* 1, 124–133. doi: 10.1016/s2352-4642(17)30010-x
- Allel, K., Stone, J., Undurraga, E. A., Day, L., Moore, C. E., Lin, L., et al. (2023). The impact of inpatient bloodstream infections caused by antibiotic-resistant bacteria in

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

Ethics statement

This study was approved by Ethics Committee of Children's Hospital, Chongqing Medical University. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

JC: Writing – original draft. HH: Data curation, Writing – review & editing. RZ: Writing – review & editing, Data curation. YF: Writing – review & editing. CJ: Writing – review & editing, Conceptualization, Resources.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

low- and middle-income countries: A systematic review and meta-analysis. *PLoS Med.* 20, e1004199. doi: 10.1371/journal.pmed.1004199

de Kraker, M. E., Jarlier, V., Monen, J. C., Heuer, O. E., van de Sande, N., and Grundmann, H. (2013). The changing epidemiology of bacteraemias in Europe: trends from the European Antimicrobial Resistance Surveillance System. *Clin. Microbiol. Infect.* 19, 860–868. doi: 10.1111/1469-0691.12028

- Dou, J. Y., Zhou, Y. P., Cui, Y., Sun, T., Shi, J. Y., Xiong, X., et al. (2024). Pathogenic characteristics and influence factors of bloodstream infection-induced severe sepsis in pediatric intensive care unit. *Zhonghua Yi. Xue. Za. Zhi.* 104, 198–204. doi: 10.3760/cma.j.cn112137-20230729-00115
- Fu, P., Xu, H., Jing, C., Deng, J., Wang, H., Hua, C., et al. (2021). Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China 2016 to 2020. *Microbiol. Spectr.* 9, e0028321. doi: 10.1128/Spectrum.00283-21
- Goldstein, B., Giroir, B., and Randolph, A. (2005). International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. *Pediatr. Crit. Care Med.* 6, 2–8. doi: 10.1097/01.Pcc.0000149131.72248.E6
- Goudie, A., Dynan, L., Brady, P. W., and Rettiganti, M. (2014). Attributable cost and length of stay for central line-associated bloodstream infections. *Pediatrics* 133, e1525–e1532. doi: 10.1542/peds.2013-3795
- Kontula, K. S. K., Skogberg, K., Ollgren, J., Järvinen, A., and Lyytikäinen, O. (2021). Population-based study of bloodstream infection incidence and mortality rates, Finland 2004–2018. *Emerg. Infect. Dis.* 27, 2560–2569. doi: 10.3201/eid2710.204826
- Laupland, K. B., and Leal, J. R. (2020). Defining microbial invasion of the bloodstream: a structured review. *Infect. Dis. (Lond.)* 52, 391–395. doi: 10.1080/23744235.2020.1727948
- Legese, M. H., Asrat, D., Swedberg, G., Hasan, B., Mekasha, A., Getahun, T., et al. (2022). Sepsis: emerging pathogens and antimicrobial resistance in Ethiopian referral hospitals. *Antimicrobial Resistance. Infect. Control.* 11, 83. doi: 10.1186/s13756-022-01122-x
- Limmathurotsakul, D. (2017). Causes and outcomes of sepsis in southeast Asia: a multinational multicentre cross-sectional study. *Lancet Global Health* 5, e157–e167. doi: 10.1016/s2214-109x(17)30007-4
- Lin, G. L., McGinley, J. P., Drysdale, S. B., and Pollard, A. J. (2018). Epidemiology and immune pathogenesis of viral sepsis. *Front. Immunol.* 9. doi: 10.3389/fimmu.2018.02147
- Lin, J. C., Spinella, P. C., Fitzgerald, J. C., Tucci, M., Bush, J. L., Nadkarni, V. M., et al. (2017). New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis: A sepsis phenotype with higher morbidity and mortality. *Pediatr. Crit. Care Med.* 18, 8–16. doi: 10.1097/pcc.0000000000000978
- Lyu, Z. Y., Zhen, J. H., Meng, Q. Y., Zhou, W., An, J. Y., and Dong, F. (2023). Bacterial etiology and antimicrobial resistance pattern of pediatric bloodstream infections in Beijing 2015–2019. *Infect. Drug Resistance.* 16, 6297–6308. doi: 10.2147/idr.S426000
- Martinón-Torres, F., Salas, A., Rivero-Calle, I., Cebej-López, M., Pardo-Seco, J., Herberg, J. A., et al. (2018). Life-threatening infections in children in Europe (the EUCLIDS Project): a prospective cohort study. *Lancet Child Adolesc. Health* 2, 404–414. doi: 10.1016/s2352-4642(18)30113-5
- McDanel, J. S., Perencevich, E. N., Diekema, D. J., Herwaldt, L. A., Smith, T. C., Chrischilles, E. A., et al. (2015). Comparative effectiveness of beta-lactams versus vancomycin for treatment of methicillin-susceptible *Staphylococcus aureus* bloodstream infections among 122 hospitals. *Clin. Infect. Dis.* 61, 361–367. doi: 10.1093/cid/civ308
- McMullan, B. J., Bowen, A., Blyth, C. C., Van Hal, S., Korman, T. M., Buttery, J., et al. (2016). Epidemiology and mortality of staphylococcus aureus bacteremia in Australian and New Zealand children. *JAMA Pediatr.* 170, 979–986. doi: 10.1001/jamapediatrics.2016.1477
- McMullan, B. J., Campbell, A. J., Blyth, C. C., McNeil, J. C., Montgomery, C. P., Tong, S. Y. C., et al. (2020). Clinical management of staphylococcus aureus bacteremia in neonates, children, and adolescents. *Pediatrics* 146, e20200134. doi: 10.1542/peds.2020-0134
- Mohamed El-Mashad, G., Said El-Mekkawy, M., and Helmy Zayan, M. (2020). Paediatric sequential organ failure assessment (pSOFA) score: A new mortality prediction score in the paediatric intensive care unit. *Pediatr. (Engl. Ed.)* 92, 277–285. doi: 10.1016/j.anpedi.2019.05.018
- Munro, C., Zilberberg, M. D., and Shorr, A. F. (2024). Bloodstream infection in the intensive care unit: evolving epidemiology and microbiology. *Antibiot. (Basel. Switzerland)* 13, 123. doi: 10.3390/antibiotics13020123
- Pai, S., Enoch, D. A., and Aliyu, S. H. (2015). Bacteremia in children: epidemiology, clinical diagnosis and antibiotic treatment. *Expert Rev. Anti-infect. Ther.* 13, 1073–1088. doi: 10.1586/14787210.2015.1063418
- Phua, J., Ngerng, W., See, K., Tay, C., Kiong, T., Lim, H., et al. (2013). Characteristics and outcomes of culture-negative versus culture-positive severe sepsis. *Crit. Care (London. England)* 17, R202. doi: 10.1186/cc12896
- Qiu, X., YP, L., and Zhou, R. X. (2023). SIRS, SOFA, qSOFA, and NEWS in the diagnosis of sepsis and prediction of adverse outcomes: a systematic review and meta-analysis. *Expert Rev. Anti-infect. Ther.* 21, 891–900. doi: 10.1080/14787210.2023.2237192
- Rhee, C., Jones, T. M., Hamad, Y., Pande, A., Varon, J., O'Brien, C., et al. (2019). Prevalence, underlying causes, and preventability of sepsis-associated mortality in US acute care hospitals. *JAMA Netw. Open* 2, e187571. doi: 10.1001/jamanetworkopen.2018.7571
- Rudd, K. E., Johnson, S. C., Agesa, K. M., Shackelford, K. A., Tsoi, D., Kievlan, D. R., et al. (2020). Global, regional, and national sepsis incidence and mortality 1990–2017: analysis for the global burden of disease study. *Lancet (London. England)* 395, 200–211. doi: 10.1016/s0140-6736(19)32989-7
- Shankar-Hari, M., Phillips, G. S., Levy, M. L., Seymour, C. W., Liu, V. X., Deutschman, C. S., et al. (2016). Developing a new definition and assessing new clinical criteria for septic shock: for the third international consensus definitions for sepsis and septic shock (Sepsis-3). *Jama* 315, 775–787. doi: 10.1001/jama.2016.0289
- Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., et al. (2016). The third international consensus definitions for sepsis and septic shock (Sepsis-3). *JAMA* 315, 801–810. doi: 10.1001/jama.2016.0287
- Tabah, A., Lipman, J., Barbier, F., Buetti, N., Timsit, J. F., and On Behalf Of The Escmid Study Group For Infections In Critically Ill Patients-Esgcip (2022). Use of antimicrobials for bloodstream infections in the intensive care unit, a clinically oriented review. *Antibiot. (Basel. Switzerland)* 11, 362. doi: 10.3390/antibiotics11030362
- Timsit, J. F., Ruppé, E., Barbier, F., Tabah, A., and Bassetti, M. (2020). Bloodstream infections in critically ill patients: an expert statement. *Intensive Care Med.* 46, 266–284. doi: 10.1007/s00134-020-05950-6
- Wang, Y., Sun, B., Yue, H., Lin, X., Li, B., Yang, X., et al. (2014). An epidemiologic survey of pediatric sepsis in regional hospitals in China. *Pediatr. Crit. Care Med.* 15, 814–820. doi: 10.1097/pcc.0000000000000247
- Weiss, S. L., Fitzgerald, J. C., Pappachan, J., Wheeler, D., Jaramillo-Bustamante, J. C., Salloo, A., et al. (2015). Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. *Am. J. Respir. Crit. Care Med.* 191, 1147–1157. doi: 10.1164/rccm.201412-2323OC
- Weiss, S. L., Peters, M. J., Alhazzani, W., Agus, M. S. D., Flori, H. R., Inwald, D. P., et al. (2020). Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. *Intensive Care Med.* 46, 10–67. doi: 10.1007/s00134-019-05878-6
- World Health Organization (2020). Global report on the epidemiology and burden of sepsis: Current evidence, identifying gaps and future directions. Available online at: <https://apps.who.int/iris/bitstream/handle/10665/334216/9789240010789-eng.pdf?ua=1> (Accessed June 8, 2024).
- Zingg, W., Hopkins, S., Gayet-Ageron, A., Holmes, A., Sharland, M., and Suetens, C. (2017). Health-care-associated infections in neonates, children, and adolescents: an analysis of paediatric data from the European Centre for Disease Prevention and Control point-prevalence survey. *Lancet Infect. Dis.* 17, 381–389. doi: 10.1016/s1473-3099(16)30517-5

Glossary

<i>A. baumannii</i>	<i>Acinetobacter baumannii</i>	IQR	inter quartile range
AKI	acute kidney injury	ISTH-DIC	international society on thrombosis and hemostasis
ALB	albumin	<i>K. pneumoniae</i>	<i>Klebsiella pneumoniae</i>
AMK	amikacin	Los	Length of stay
AMC	amoxicillin/clavulanate	P/F value	oxygenation index (PaO ₂ /FiO ₂)
ATM	aztreonam	LVX	levofloxacin
BSI	bloodstream infection	MEM	meropenem
CHL	chloramphenicol	MV	mechanical ventilation
CIP	ciprofloxacin	NA	not applicable
CoNS	<i>Coagulase-negative staphylococci</i>	OXA	oxacillin
CR-ECO	carbapenem-resistant <i>E. coli</i>	<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
CR-KPN	carbapenem-resistant <i>K. pneumoniae</i>	PCT	Procalcitonin
CRO	ceftriaxone	PEN	Penicillin
CRP	C-reactive protein	PICU	Pediatric intensive care unit
CRRT	continuous renal replacement therapy	pSOFA	pediatric sequential organ failure assessment
CXM	cefuroxime	R	resistance
<i>E. coli</i>	<i>Escherichia coli</i>	RIF	rifampicin
DTR	difficult-to-treat resistance	<i>S.aureus</i>	<i>Staphylococcus aureus</i>
ECR	extended-spectrum cephalosporin resistance	SAM	ampicillin-sulbactam
ERY	erythromycin	SCr	serum creatinine
FEP	cefepime	SIC	Sepsis-induced coagulopath scores
Fib	fibrinogen	SP	<i>Streptococcus pneumoniae</i>
FOX	cefoxitin	SXT	trimethoprim-sulfamethoxazole
FQR	fluoroquinolone resistance	TCY	tetracycline
GEN	gentamicin	TZP	piperacillin/tazobactam
GNB	gram-negative bacteria	VAN	vancomycin
GPB	gram-positive bacteria	IPM	imipenem
I	intermediate	WBC	White blood cell